Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.63 |
| ▸ | MAPK8 | P45983 | 13/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141410 | 0.85 | PTPN2 (0.62) | PTK2MAPK8MAPK10ALDH1A1KMT2A | |
| SCHEMBL18080772 | 0.82 | PTK2 (0.66) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL166147 | 0.81 | MAPK8 (0.60) | PTK2MAPK8MAPK10NPC1RAB9A | |
| SCHEMBL1680689 | 0.80 | PTK2 (0.73) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL13270043 | 0.79 | PTK2 (0.71) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL11946878 | 0.79 | PTK2 (0.71) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL23323409 | 0.77 | PTK2 (0.69) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL5092793 | 0.77 | PTK2 (1.00) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL4144089 | 0.77 | KMT2A (0.47) | PTK2MAPK8MAPK10ALDH1A1MAPT | |
| SCHEMBL16338303 | 0.76 | PTK2 (0.57) | PTK2MAPK8MAPK10ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | PTK2 2823/4885MAPK8 2560/4885MAPK10 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.